Journal of Advances in Leukemia

Journal of Advances in Leukemia

Journal of Advances in Leukemia – About

Open Access & Peer-Reviewed

Submit Manuscript

Journal of Advances in Leukemia

Advancing Discovery and Clinical Excellence in Leukemia Research Through Rigorous Peer-Reviewed Scholarship

The Journal of Advances in Leukemia (JAL) serves as a premier platform for disseminating cutting-edge research in leukemia science, bridging fundamental discovery with clinical translation. As a peer-reviewed, open access journal, JAL provides immediate global visibility to high-quality investigations that advance our understanding of leukemia pathogenesis, diagnosis, treatment, and outcomes.

JAL welcomes contributions from basic scientists, clinical researchers, hematologists, oncologists, and healthcare professionals worldwide. Our commitment to rigorous peer review, efficient online publication, and unrestricted access ensures that breakthrough findings reach the broadest possible audience, supporting progress against these devastating blood cancers.

Our Mission

To advance the scientific understanding and clinical management of leukemia by publishing innovative, methodologically sound research that transforms patient care and outcomes.

We are dedicated to fostering a collaborative international community where researchers share discoveries that illuminate disease mechanisms, refine diagnostic approaches, optimize therapeutic strategies, and improve quality of life for patients worldwide.

Core Values

★

Scientific Excellence

Rigorous methodology, reproducible results, and meaningful contributions to leukemia knowledge.

★

Transparent Process

Fair, constructive peer review with clear ethical standards and author support.

🌐

Global Accessibility

Open access publishing removes barriers, democratizing knowledge for all stakeholders.

Research Scope

JAL publishes multidisciplinary research spanning the full spectrum of leukemia science and clinical care

Disease Biology & Mechanisms

  • Molecular pathogenesis of acute and chronic leukemias
  • Genetic and epigenetic alterations
  • Signal transduction pathways
  • Leukemic stem cell biology
  • Microenvironment interactions

Diagnostics & Classification

  • Novel biomarker discovery and validation
  • Advanced cytogenetic techniques
  • Molecular diagnostic methods
  • Risk stratification systems
  • Minimal residual disease detection

Therapeutic Advances

  • Targeted therapy development
  • Immunotherapy approaches
  • Chemotherapy optimization
  • Stem cell transplantation
  • Drug resistance mechanisms

Clinical Outcomes & Care

  • Clinical trial results
  • Treatment protocols and guidelines
  • Survivorship and quality of life
  • Supportive care strategies
  • Health services research

Pediatric Leukemia

  • Age-specific disease characteristics
  • Childhood leukemia subtypes
  • Developmental considerations
  • Long-term survivor outcomes
  • Family-centered care approaches

Emerging Technologies

  • Next-generation sequencing applications
  • Single-cell analysis techniques
  • Artificial intelligence in diagnosis
  • Novel drug delivery systems
  • Precision medicine platforms

Article Types We Welcome

Original Research Clinical Trials Case Reports Review Articles Short Communications Letters to Editor Editorials Systematic Reviews

Expert Editorial Leadership

JAL is guided by an international editorial board comprising distinguished hematologists, oncologists, molecular biologists, and clinical researchers with expertise across all leukemia subtypes. Our editors are committed to maintaining the highest standards of scientific integrity while providing constructive guidance to authors.

This collaborative approach ensures thorough, fair peer review that strengthens manuscripts and advances the field. Our editorial team works diligently to provide timely decisions and support authors throughout the publication process.

Meet Our Editorial Board

Our Commitment to Authors

Thorough and Timely Peer Review

Efficient peer review process with constructive feedback to move science forward.

Open Access

Immediate, unrestricted access to published articles ensures maximum visibility and impact for your research.

Author Support

Dedicated editorial assistance from submission through publication, ensuring a smooth publishing experience.

Ethical Standards

Strict adherence to publication ethics guidelines, protecting research integrity and author rights throughout.

Why Publish With JAL?

Global Reach: Open access publishing ensures your research reaches clinicians, researchers, and patients worldwide without subscription barriers, maximizing your contribution's impact on leukemia care.

Multidisciplinary Audience: JAL attracts readers from basic science, translational research, and clinical practice, facilitating cross-disciplinary dialogue that accelerates bench-to-bedside innovation.

Rigorous Standards: Expert peer review maintains scientific quality while constructive feedback strengthens your manuscript, enhancing its contribution to the field.

Efficient Online Publication: Streamlined editorial workflows and efficient production processes support the dissemination of your findings, keeping pace with the rapidly evolving leukemia landscape.

Join the Global Community Advancing Leukemia Research

Publication frequency: continuous publication. Articles are published online individually once production is complete and are added to the current volume and issue; volumes and issues do not follow a fixed calendar schedule.

Publisher policies: Complaints and appeals · AI use policy · Publication ethics